Personalized Medicine Phenytoin Therapy

Em Sutrisna

Personalized Medicine Phenytoin Therapy

Em Sutrisna

Abstract

Phenytoin is one of the antiepileptic drugs most widely prescribed. This drug has narrow therapeutic index, and often treated for a long time. Phenytoin was metabolized by CYP2C9 (major) and CYP2C19 (minor). The purpose of this review is to give a comprehensive understanding of the influence of genetic polymorphisms toward phenytoin response. The methods of review were searching through Pubmed with keywords pharmacogenetic, phenytoin and epileptic. We found 41 journals but only 19 met the criteria, namely: a. human subjects, b. discuss the impact of genetic responses phenytoin. The author adds 1 journal, 1 web (drug bank) and books so that became 22. Search results conclude that: the polymorphisms of genes of metabolizing enzyme (CYP) affect to the kinetic profile of phenytoin.

Keywords

phenytoin, CYP, pharmacogenetic

Full Text:

References

von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy. 2008;28(11):1391–1400.

Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. PNAS. 2005;102(15): 5507–5512.

Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Mon it. 2013;35(1):4–29.

Anderson GD. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Mon. 2008;30(2):173–180.

Drugbank, Phenytoin, http://www.drugbank.ca/drugs/DB00252. di akses Januari 2016.

Porter RJ, Meldrum BS. Antiseizure drugs. In B.G. Katzung (Ed) Basic and clinical pharmacology, 10th ed Mc Graw Hill. 2006.

Neurvonen PJ. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet.1979;4(2):91–103.

Nakajima M, Sakata N, Ohashi N, Kume T, Yokoi T. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4’-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. Drug Metab Dispos. 2002;30(11):1250–1256.

Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–1276.

van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001;11(4):287–291.

Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol. 1993;43(2):234–239.

Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol. 2007;40(3):448–452.

de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46(4):594–598.

de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269(22):15419–15422.

Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C 19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 1998;39 (12):1317–1323.

Dorado P, López-Torres E, Peñas-Lledó EM, Martínez-Antón J, Llerena A. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 2013;13(4):359–361.

Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, et al. Site-directed mutation studies of human liver cytochrome P-450 isozymes in the CYP2C subfamily. Biochem. J. 1993;289(Pt 2):533–538.

Jose L, Binila C, Chandy SJ, Mathews JE, Mathews KP. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. J Assoc Physicians India. 2008;56:250–252.

Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and

phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–2091.

Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian

patients: a gene polymorphism perspective study. Ther Drug Monit. 2007;29(3):305–312.

Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11(9):803–808.

Askitosari TD. Frekuensi alel gen pemetabolisme obat CYP2C9*3 dan CYP 2C19*17 pada populasi suku bugis di Makassar. 2011. Thesis. Jogjakarta.

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Journal of Pharmaceutical and Biomedical Sciences